Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple Myeloma
- Interventions
- Drug: Aurora A kinase inhibitor MLN8237Drug: bortezomib
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 26
- Registration Number
- NCT01034553
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Retreatment Study With Bortezomib for Multiple Myeloma
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 56
- Registration Number
- NCT01030302
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT01029730
- Locations
- 🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸Hematology Oncology of the North Shore, Skokie, Illinois, United States
🇺🇸Holy Cross Hospital, Ft. Lauderdale, Florida, United States
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 104
- Registration Number
- NCT01026701
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 767
- Registration Number
- NCT01023308
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 140
- Registration Number
- NCT01021592
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
- Conditions
- AIDS-Related Kaposi SarcomaRecurrent Kaposi SarcomaHIV Infection
- Interventions
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01016730
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2014-09-25
- Target Recruit Count
- 30
- Registration Number
- NCT01009840
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Maryland School of Medicine - Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 1121
- Registration Number
- NCT01005628
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 135
- Registration Number
- NCT01002248
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇮🇪Keryx / AOI Pharmaceuticals Investigative Site, Dublin 7, Ireland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.